• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·1733.TW
Share

Apex Biotechnology Corp. Stocks

NT$ 28.95Last Updated 13.11.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 88.01M

NT$ 28.95
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup features a variety of personal health monitoring systems, including those for tracking blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1c, and ketone levels. In addition, the company provides self-testing solutions for coagulation and multi-parameter analysis, alongside advanced hemoglobin screening systems. Beyond patient diagnostics, Apex Biotech also offers systems for detecting pesticide residues. The company further extends its services to include digital care management and telehealth platforms. Established in 1997, Apex Biotechnology Corp. operates from its headquarters located in Hsinchu City, Taiwan.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.11.2026 17:01

What's New in Small-Cap Stocks: The Forbes Ranking, Oklo's Plans for Meta, and Ceco's Record

14.11.2026 13:01

Is There Life After Huang? The Rise of Anthropic, and the AI Rally in the Clouds

14.11.2026 04:56

Key Starship tests did not go as planned. SpaceX shares fell

14.11.2026 04:35

The S&P 500 posted its best week in six months. Barclays expects growth for the first time since March

14.11.2026 03:40

Huang still holds $135 billion worth of Nvidia stock. Why is this worrying investors?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026